Medical Business Based on Self-Assembling Peptides
First written in FY2016. 26 of 28 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026RestatedAnnual report
「Our corporate philosophy is to “contribute to the advancement of medicine through biomaterials.” We will continue developing products in the surgical, tissue regeneration and other fields, while working to achieve global competitiveness.」
The Group has reaffirmed its basic policy of continuing to develop medical products in surgery, tissue regeneration and other fields based on self-assembling peptide technology, with the aim of achieving global competitiveness. - FY2025RestatedAnnual report
「Our corporate philosophy is to “contribute to the advancement of medicine through biomaterials.” We will continue developing products in the surgical, tissue regeneration and other fields, while working to achieve global competitiveness.」
The Group has reaffirmed its basic policy of continuing to develop medical products in surgery, tissue regeneration and other fields based on self-assembling peptide technology, with the aim of achieving global competitiveness. - FY2024-Q3RestatedAnnual report
「The Group continues to focus on the development, manufacture and sale of medical products based on self-assembling peptide technology invented by researchers at the Massachusetts Institute of Technology (MIT) in the United States.」
The Group has reaffirmed its policy of developing, manufacturing and selling medical products based on self-assembling peptide technology invented by MIT researchers. - FY2024-Q2RestatedAnnual report
「The Group continues to focus on the development, manufacture and sale of medical products based on self-assembling peptide technology invented by researchers at the Massachusetts Institute of Technology (MIT) in the United States.」
The Group has reaffirmed its basic policy of continuing to develop, manufacture and sell medical products based on self-assembling peptide technology invented by MIT researchers. - FY2023-Q2ReframedAnnual report
「Going forward, the Group will leverage the technological advantages of self-assembling peptides and adopt a globally optimized development and sales strategy, drawing on the strengths of its three-region presence in the tissue regeneration and DDS fields, where even greater future demand is expected.」
While maintaining its policy of using self-assembling peptide technology as its foundation, the Group is expanding its focus beyond surgery to tissue regeneration and DDS, adopting a globally optimized development and sales strategy that leverages its presence in Japan, the United States and Europe. - FY2023-Q1RestatedAnnual report
「The Group continues to focus on the development, manufacture and sale of medical products based on self-assembling peptide technology invented by researchers at the Massachusetts Institute of Technology (MIT) in the United States.」
The Group has reaffirmed its policy of developing, manufacturing and selling medical products based on self-assembling peptide technology invented by MIT researchers. - FY2022RestatedAnnual report
「The Group continues to focus on the development, manufacture and sale of medical products based on self-assembling peptide technology invented by researchers at the Massachusetts Institute of Technology (MIT) in the United States.」
The Group has reaffirmed its policy of developing, manufacturing and selling medical products based on MIT-derived self-assembling peptide technology. - FY2022-Q3RestatedAnnual report
「The Group continues to focus on the development, manufacture and sale of medical products based on self-assembling peptide technology invented at the Massachusetts Institute of Technology (MIT) in the United States.」
The Group has reaffirmed its basic policy of continuing to develop, manufacture and sell medical products based on MIT-derived self-assembling peptide technology. - FY2022-Q2RestatedAnnual report
「The Group continues to focus on the development, manufacture and sale of medical products based on self-assembling peptide technology invented by Dr. Shuguang Zhang of the Massachusetts Institute of Technology (MIT) in the United States.」
The Group has reaffirmed its basic policy of developing, manufacturing and selling medical products in the surgical, regenerative medicine and DDS fields based on MIT-derived self-assembling peptide technology. - FY2022-Q1RestatedAnnual report
「The Group continues to focus on the development, manufacture and sale of medical products based on self-assembling peptide technology invented by Dr. Shuguang Zhang of the Massachusetts Institute of Technology (MIT) in the United States.」
The Group has reaffirmed its basic policy of continuing to develop, manufacture and sell medical products in the surgical, regenerative medicine and DDS fields based on MIT-derived self-assembling peptide technology. - FY2021RestatedAnnual report
「Our corporate philosophy is to “contribute to the advancement of medicine through biomaterials.” We will continue developing differentiated products in the surgical and regenerative medicine fields and elsewhere, while working to achieve global competitiveness.」
The Group has reaffirmed its basic policy of developing differentiated medical products in surgery, regenerative medicine and other fields based on self-assembling peptides, with the aim of achieving global competitiveness. - FY2021-Q3RestatedAnnual report
「The Group continues to focus on the development, manufacture and sale of medical products based on self-assembling peptide technology invented at the Massachusetts Institute of Technology (MIT) in the United States.」
The Group has reaffirmed its policy of developing, manufacturing and selling medical products based on MIT-derived self-assembling peptide technology. - FY2021-Q2RestatedAnnual report
「The Group continues to focus on the development, manufacture and sale of medical products based on self-assembling peptide technology invented at the Massachusetts Institute of Technology (MIT) in the United States.」
The Group has reaffirmed its basic policy of developing, manufacturing and selling medical products based on MIT-derived self-assembling peptide technology. - FY2021-Q1RestatedAnnual report
「The Group continues to focus on the development, manufacture and sale of medical products based on self-assembling peptide technology invented at the Massachusetts Institute of Technology (MIT) in the United States.」
The Group has reaffirmed its basic policy of continuing to develop, manufacture and sell medical products in the surgical, regenerative medicine and DDS fields based on MIT-derived self-assembling peptide technology. - FY2020-Q3RestatedAnnual report
「The Group continues to focus on the development, manufacture and sale of medical products based on self-assembling peptide technology, an invention of Dr. Shuguang Zhang of the Massachusetts Institute of Technology (MIT) in the United States.」
The Group has reaffirmed its basic policy of continuing to develop, manufacture and sell medical products in the surgical, regenerative medicine and DDS fields based on self-assembling peptide technology. - FY2020-Q2RestatedAnnual report
「The Group continues to focus on the development, manufacture and sale of medical products based on self-assembling peptide technology, an invention of Dr. Shuguang Zhang of the Massachusetts Institute of Technology (MIT) in the United States.」
The Group has reaffirmed its policy of developing, manufacturing and selling medical products based on self-assembling peptide technology. - FY2020-Q1RestatedAnnual report
「The Group continues to focus on the development, manufacture and sale of medical products based on self-assembling peptide technology, an invention of Dr. Shuguang Zhang of the Massachusetts Institute of Technology (MIT) in the United States.」
The Group has reaffirmed its basic policy of continuing to develop, manufacture and sell medical products in the surgical, regenerative medicine and DDS fields based on self-assembling peptide technology. - FY2019-Q3RestatedAnnual report
「The Group continues to focus on developing medical products based on its core self-assembling peptide technology.」
The Group has reaffirmed its basic policy of continuing to develop medical products centered on self-assembling peptide technology. - FY2019-Q2RestatedAnnual report
「The Group continues to focus on developing medical products based on its core self-assembling peptide technology.」
The Group has reaffirmed its basic policy of continuing to develop medical products in the surgical, regenerative medicine and DDS fields, centered on self-assembling peptide technology. - FY2019-Q1RestatedAnnual report
「The Group continues to focus on developing medical products based on its core self-assembling peptide technology.」
The Group reaffirmed its basic policy of advancing medical product development centered on self-assembling peptide technology. - FY2018RestatedAnnual report
「Our corporate philosophy is to “contribute to the advancement of medicine through biomaterials.” We will continue developing differentiated products in the surgical and regenerative medicine fields and elsewhere, while working to achieve global competitiveness.」
The Group maintains its basic policy of developing differentiated medical products in surgery, regenerative medicine and other fields based on self-assembling peptides, with the aim of achieving global competitiveness. - FY2018-Q3RestatedAnnual report
「The Group continues to focus on developing medical products based on its core self-assembling peptide technology. In the surgical field, it has been developing the absorbable local hemostatic agent TDM-621 (the "Hemostatic Agent") and the mucosal elevation agent TDM-641 (the "Mucosal Elevation Agent"), while in regenerative medicine it has been advancing the business development of the alveolar bone reconstruction material TDM-711 (the "Alveolar Bone Reconstruction Material") and the wound-healing material TDM-511 (the "Wound-Healing Material").」
The Group maintains its basic policy of developing and commercializing multiple products in the surgical and regenerative medicine fields, with self-assembling peptide technology at its core. - FY2018-Q2RestatedAnnual report
「The Group continues to focus on developing medical products based on its core self-assembling peptide technology. In the surgical field, it has been developing the absorbable local hemostatic agent TDM-621 (the "Hemostatic Agent") and the mucosal elevation agent TDM-641 (the "Mucosal Elevation Agent"), while in regenerative medicine it has been advancing the business development of the alveolar bone reconstruction material TDM-711 (the "Alveolar Bone Reconstruction Material") and the wound-healing material TDM-511 (the "Wound-Healing Material").」
The Group maintains its basic policy of developing and commercializing multiple products in surgery and regenerative medicine, centered on self-assembling peptide technology. - FY2018-Q1RestatedAnnual report
「The Group continues to focus on developing medical products based on its core self-assembling peptide technology. In the surgical field, it has been developing the absorbable local hemostatic agent TDM-621 (the "Hemostatic Agent") and the mucosal elevation agent TDM-641 (the "Mucosal Elevation Agent"), while in regenerative medicine it has been advancing the business development of the alveolar bone reconstruction material TDM-711 (the "Alveolar Bone Reconstruction Material") and the wound-healing material TDM-511 (the "Wound-Healing Material").」
The Group maintains its basic policy of developing and commercializing multiple products in surgery and regenerative medicine, centered on self-assembling peptide technology. - FY2017-Q3RestatedAnnual report
「The Group continues to focus on developing medical products based on its core self-assembling peptide technology. In the surgical field, it has been developing the absorbable local hemostatic agent TDM-621 (the "Hemostatic Agent") and the mucosal elevation agent TDM-641 (the "Mucosal Elevation Agent"), while in regenerative medicine it has been advancing the business development of the alveolar bone reconstruction material TDM-711 (the "Alveolar Bone Reconstruction Material") and the wound-healing material TDM-511 (the "Wound-Healing Material").」
The Group continues to focus on multiple products in surgery and regenerative medicine, using self-assembling peptide technology as its core technology. - FY2017-Q2RestatedAnnual report
「The Group continues to focus on developing medical products based on its core self-assembling peptide technology. In the surgical field, it has been developing the absorbable local hemostatic agent TDM-621 (the "Hemostatic Agent") and the mucosal elevation agent TDM-641 (the "Mucosal Elevation Agent"), while in regenerative medicine it has been advancing the business development of the alveolar bone reconstruction material TDM-711 (the "Alveolar Bone Reconstruction Material") and the wound-healing material TDM-511 (the "Wound-Healing Material").」
The Group continues to focus on multiple products in surgery and regenerative medicine, using self-assembling peptide technology as its core technology. - FY2017-Q1RestatedAnnual report
「The Group continues to focus on developing medical products based on its core self-assembling peptide technology. In the surgical field, it has been developing the absorbable local hemostatic agent TDM-621 (the "Hemostatic Agent") and the mucosal elevation agent TDM-641 (the "Mucosal Elevation Agent"), while in regenerative medicine it has been advancing the business development of the alveolar bone reconstruction material TDM-711 (the "Alveolar Bone Reconstruction Material") and the wound-healing material TDM-511 (the "Wound-Healing Material").」
The Group continues to focus on multiple products in surgery and regenerative medicine, using self-assembling peptide technology as its core technology. - FY2016First statedAnnual report
「The Group is developing medical devices and pharmaceuticals in the surgical, regenerative medicine and DDS fields, based on its self-assembling peptide technology as a core technology.」
The Group's basic policy is to develop medical products across multiple fields, including surgery, regenerative medicine and DDS, centered on self-assembling peptides.